Collaborators |
Product |
Indication |
Funding |
Summary |
 |
National Institutes of Allergy and Infectious Diseases (NIAID) |
CEL-1000 |
Avian (bird) flu |
Testing conducted and paid for by NAID |
Testing conducted to determine whether CEL-1000 could be used as a potential treatment and/or preventative agent against this virus. |
|
John Hopkins University |
L.E.A.P.S.™ |
Myocarditis (precusor to dilated cardiomyopathy) |
Maryland Industrial Partnership (MIPS) & Governmnent grants |
Pretreatment and early therapy of Experimental Autoimmune Myocarditis with CEL-1000 resulted in significant reduction of heart enlargement and disease associated histopathological changes in animal models. |
|
Northeastern Ohio Universities College of Medicine (NEUOCOM) |
CEL-1000 |
Viral Encephalitis (VE) |
U-01 Grant ($1,100,00) |
Was shown in mice to protect against VE, a potentially lethal inflamation of the brain. VE is on the U.S. government's list of priority pathogens for bio-defense research. |
|
U.S. Navy |
L.E.A.P.S.™
& CEL-1000 |
Malaria |
Cooperative Research and Development Agreement (CRADA) |
The initial tests conducted in mice. It has been reported that CEL-1000 was 100% protective in mice. Once the optimal combination has been determined, the product will be further tested in primates. |
|
National Instutes of Health (NIH) & the U.S. Army |
CEL-1000 |
SARS, smallpox, vaccinia, West Nile virus |
Cooperative Agreement |
The testing will be conducted to detemine whether CEL-1000 could be used as a potential treatment and/or preventive agent against these diseases. |
|
University of Nebraska Medical Center |
CEL-1000 |
Vaccinia and Smallpox infection |
Phase I SBIR Grant ($104,000) |
The development as a potential therapeutic and prophylactic agent against vaccinia and smallpox infections as a single agent and as an adjuvant for vaccinia vaccines. |
|
Northeastern Ohio Universities College of Medicine (NEUOCOM) |
L.E.A.P.S.™
& CEL-1000 |
Herpes Simplex Virus (HSV) |
Phase I and II SBIR Grants ($1,026,000) |
CEL-1000 prevents or reduces morbidity and mortality of HSV in mice tested as a treatment, and LEAPS as a vaccine. |
